XML 32 R14.htm IDEA: XBRL DOCUMENT
v3.24.0.1

DISCONTINUED OPERATIONS | 12 Months Ended
--- | ---
Dec. 31, 2023
Discontinued Operations and Disposal Groups [Abstract] |
DISCONTINUED OPERATIONS | 5. DISCONTINUED OPERATIONS On January 25, 2021, we entered into an agreement with Medici Ventures, Pelion, and Pelion, Inc. (the "Medici Closing"), pursuant to which Medici Ventures converted to a Delaware limited partnership (the "Partnership") and Pelion became the sole general partner of the Partnership, and we became the limited partner of the Partnership. The term of the Partnership is eight years. A tZERO debt conversion was completed during the quarter ended March 31, 2021, following which Medici Ventures and Beyond held approximately 42% and 41%, respectively, of tZERO's outstanding common stock. On April 23, 2021, we entered into the Limited Partnership Agreement with Pelion, pursuant to which Pelion became the sole general partner, holding a 1% equity interest in the Partnership, and Beyond became a limited partner, holding a 99% equity interest in the Partnership. Our retained equity interest in these entities are classified as equity method securities as we are deemed to have significant influence, but not control, over these entities through holding more than a 20% interest in the entity. At the Medici Closing, our retained equity interest in the Partnership and our direct minority interest in tZERO had a fair value of $288.8 million, inclusive of $3.4 million of capital calls funded at the Medici Closing. The fair value of these equity securities at the Medici Closing was estimated by taking the mid-point from a valuation range using a weighting of multiple valuation techniques on the underlying components of the equity securities to calculate a fair value for the whole, including discounted cash flow models and market transactional data, both of which incorporate significant unobservable inputs (Level 3). Approximately $149.9 million of the total $288.8 million Level 3 equity securities have been valued using unadjusted inputs that have not been internally developed by management, including third-party transactions and quotations. The significant unobservable inputs used in the $288.8 million fair value measurement of these Level 3 equity securities at the Medici Closing are summarized as follows:
Valuation Technique |  | Unobservable Inputs |  | Range (1) |  | Weighted Average (2)
Market approach |  | Enterprise value to revenue multiple |  | 0.88x |  | 0.88x
Discounted cash flows – exit multiple |  | Discount rate |  | 9.0% - 35.0% |  | 32.4%
| Enterprise value to revenue multiple |  | 0.75x – 5.00x |  | 4.40x
| Projected terminal year |  | 2023 – 2027 |  | 2025
| Annual revenue growth rate |  | 1.3% - 124.0% |  | 109.4%
| Annual EBITDA % of revenues |  | 5.2% - 41.2% |  | 36.3%
Discounted cash flows – perpetual growth |  | Discount rate |  | 30.0% |  | 30.0%
| Projected terminal year |  | 2028 |  | 2028
| Perpetual revenue growth rate |  | 3.0% |  | 3.0%
| Annual revenue growth rate |  | 25.7% |  | 25.7%
| Annual EBITDA % of revenues |  | 14.9% |  | 14.9%
__________________________________________ (1) — The range for the Annual revenue growth rate and Annual EBITDA % of revenues are based on the weighted average metrics for the annual periods of the separate cash flow models for the respective component. (2) — Unobservable inputs were weighted by the relative fair value based on the fair value of the underlying components subjected to the identified valuation technique. For projected terminal year, the amount represents the median of the inputs and is not a weighted average. We recognized a $243.5 million gain upon deconsolidation of these entities which primarily relates to the remeasurement of our retained equity method interest in the Partnership and our direct minority interest in tZERO at fair value, which was included in our consolidated statements of operations as part of Income from discontinued operations, net of income taxes. We completed the entire funding of our $44.6 million capital commitment consistent with our proportional ownership interest, which was completed and funded in the second quarter of 2021. Results of discontinued operations through the transaction date were as follows (in thousands):
|  |  | Year ended December 31,
|  |  |  |  | 2023 |  | 2022 |  | 2021
Net revenue |  |  |  |  | $ | — |  |  | $ | — |  |  | $ | 17,394 |
Cost of goods sold |  |  |  |  | — |  |  | — |  |  | 13,716 |
Gross profit |  |  |  |  | — |  |  | — |  |  | 3,678 |
Operating expenses |  |  |  |  |  |  |  |  |
Technology |  |  |  |  | — |  |  | — |  |  | 7,133 |
Selling, general, and administrative |  |  |  |  | — |  |  | — |  |  | 13,509 |
Total operating expenses |  |  |  |  | — |  |  | — |  |  | 20,642 |
Operating loss from discontinued operations |  |  |  |  | — |  |  | — |  |  | (16,964) |
Interest income, net |  |  |  |  | — |  |  | — |  |  | 192 |
Other income, net |  |  |  |  | — |  |  | — |  |  | 4,081 |
Gain on deconsolidation |  |  |  |  | — |  |  | — |  |  | 243,541 |
Income from discontinued operations before income taxes |  |  |  |  | — |  |  | — |  |  | 230,850 |
Provision for income taxes |  |  |  |  | — |  |  | — |  |  | 13,604 |
Income from discontinued operations, net of income taxes |  |  |  |  | $ | — |  |  | $ | — |  |  | $ | 217,246 |
Less: Net loss attributable to noncontrolling interests from discontinued operations |  |  |  |  | — |  |  | — |  |  | (335) |
Net income from discontinued operations attributable to stockholders of Beyond, Inc. |  |  |  |  | $ | — |  |  | $ | — |  |  | $ | 217,581 |

X
- References No definition available. + Details
Name: | us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205-20/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//360/tableOfContent + Details
Name: | us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration